AI
DSGN icon

Atom Investors’s Design Therapeutics DSGN Stock Holding History

Atom Investors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,890
Closed -$68.6K – 315
2023
Q1 		$68.6K Buy
+11,890
New +$88.9K 0.04% 232

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Atom Investors's DSGN Position: Q2 2023 in Review

Atom Investors sold out of Design Therapeutics (DSGN) in Q2 2023, closing a stake of 11,890 shares — an estimated $68.6K sold.

Atom Investors first reported a position in DSGN in Q1 2023 and held it in 1 quarter. The position peaked at $68.6K in Q1 2023. 97 funds tracked by Wall St. Rank hold DSGN as of Q2 2023.

  • Atom Investors reported no remaining Design Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Atom Investors sold 11,890 Design Therapeutics shares in Q2 2023, an estimated $68.6K.
  • Atom Investors first reported a position in Design Therapeutics in Q1 2023 and held it in 1 quarter.
  • Atom Investors's Design Therapeutics position peaked at $68.6K in Q1 2023.
  • 97 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2023.

Based on Atom Investors's 13F filing for Q2 2023, filed 14 Aug 2023.